Press Releases
Page 11 • 12 itemsAccess critical pharma & biotech press releases. Stay ahead on drug approvals, clinical trials, M&A, and regulatory updates impacting global markets.
HYTN Innovations Launches HARd Cannabis Remediation Technology for GMP Processing Services in Germany
HYTN Innovations introduces proprietary HARd remediation technology for cannabis flower processing, expanding GMP services with German market launch.
Sanofi's Nuvaxovid COVID-19 Vaccine Shows Superior Tolerability Over mNEXSPIKE in Phase 4 Study
Sanofi's protein-based Nuvaxovid COVID-19 vaccine demonstrated better tolerability than mNEXSPIKE in first head-to-head phase 4 study presented at ESCMID.
Brand Institute Receives First EMA Approval for AI-Developed Pharmaceutical Brand Name Using Brandi Platform
Brand Institute achieves regulatory milestone as EMA approves first pharmaceutical brand name developed using AI-powered Brandi platform technology.
EMA Approves Hanmi Pharmaceutical's HMPL-523 Herbal Medicine for Alzheimer's Disease Treatment
European Medicines Agency grants marketing authorization for HMPL-523, marking first herbal medicine approval for mild to moderate Alzheimer's disease treatment.
Gene Therapy Market to Reach $43.8 Billion by 2034 as CRISPR and AAV Technologies Drive 12.27% Annual Growth
Gene therapy market projected to grow 12.27% annually through 2034, driven by CRISPR and AAV advances, with North America leading at 56% market share.
Healthcare Cold Chain Logistics Market to Surge Through 2034 as Biopharmaceutical Demand Drives Asia-Pacific Growth
Healthcare cold chain logistics market projected for significant growth 2026-2034, driven by rising biopharmaceutical demand and Asia-Pacific expansion.
AIM ImmunoTech Advances Ampligen to Phase 3 Pancreatic Cancer Trial with Orphan Drug Status
AIM ImmunoTech plans Phase 3 trial for Ampligen in pancreatic cancer, backed by positive Phase 2 data and orphan drug designations in US and Europe.
AB Science Secures €25 Million Clinical Trial Insurance for Masitinib ALS Phase III Study
AB Science obtains €25M clinical trial insurance for masitinib ALS Phase III study while implementing temporary European trial halt amid regulatory review.
MeiraGTx Acquires Botaretigene Sparoparvovec Gene Therapy from Johnson & Johnson for X-linked Retinitis Pigmentosa Treatment
MeiraGTx acquired botaretigene sparoparvovec from J&J to treat X-linked retinitis pigmentosa, planning immediate global regulatory filings for approval.
Beamion's Zongertinib Receives FDA Accelerated Approval for HER2-Mutant NSCLC as LUNG-1 Study Results Published in NEJM
Beamion's zongertinib gains FDA accelerated approval for HER2-mutant NSCLC treatment following breakthrough therapy designation and NEJM publication.
TRI-611 Receives FDA Fast Track Designation for ALK-Positive Non-Small Cell Lung Cancer as Competition Intensifies
TRI-611 molecular glue degrader gains FDA fast track status for ALK-positive NSCLC while Eisai's taletrectinib advances in Europe for ROS1+ lung cancer treatment.
Traws Pharma Advances Tivoxavir Marboxil to Human Influenza Challenge Trial, Reports Positive Ratutrelvir COVID Data
Traws Pharma advances tivoxavir marboxil for once-monthly flu prevention and reports differentiated COVID treatment data for ratutrelvir versus Paxlovid.